- |||||||||| TQ-F3083 / Centaurus Biopharma
Clinical, P1 data, Journal: First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults. (Pubmed Central) - Aug 10, 2021
The concentration of active glucagon-like peptide-1 increased after TQ-F3083 administration, but no obvious dose dependency was observed. TQ-F3083 was well tolerated in healthy Chinese adults, and the pharmacokinetic and pharmacodynamic characteristics support further evaluation of TQ-F3083 in a trial in T2DM patients.
- |||||||||| TQ-F3083 / Centaurus Biopharma
Enrollment open, Trial initiation date: Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Mar 13, 2020
P2a, N=120, Recruiting,
TQ-F3083 was well tolerated in healthy Chinese adults, and the pharmacokinetic and pharmacodynamic characteristics support further evaluation of TQ-F3083 in a trial in T2DM patients. Not yet recruiting --> Recruiting | Initiation date: Jul 2019 --> Jan 2020
|
